Immune response against pneumococcal vaccination in patients after pneumonia
Completed
- Conditions
- immune responspneumococcal vaccinationpneumococcal conjugate vaccinationPCV13pneumonia
- Registration Number
- NL-OMON21679
- Lead Sponsor
- Sint Antonius Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 140
Inclusion Criteria
1. Patients who participated in the Ovidius or Triple-P study (2004-2009).
2. Diagnosis in these studies with pneumococcal pneumonia or pneumonia due another identified organism.
Exclusion Criteria
Changed 2-sep-2014:
1. Diagnosis of pneumonia without an identified causative organism.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immune response to pneumococcal vaccination in patients who were diagnosed with CAP due to S. pneumoniae in comparison with patients with another causative pathogen. Main parameters are antibody titres against the different<br>pneumococcal serotypes before and after vaccination and avidity maturation of these antibodies.
- Secondary Outcome Measures
Name Time Method • To investigate antibody response after pneumococcal vaccination in patients with community acquired pneumococcal<br>pneumonia in the past who failed to elicit a specific antibody response previously. <br /><br>• To investigate the cellular immune responses after pneumococcal vaccination in patients with community acquired pneumococcal pneumonia in the past compared to pneumonia patients with another pathogen.<br /><br>• To investigate quality of life by the RAND-36 score in patients with a community acquired pneumonia in the past. <br /><br>• To investigate the long-term mortality after community acquired pneumococcal pneumonia.